Glaukos Corporation (GKOS) Shares are Up 16.38%

Glaukos Corporation (GKOS) : Traders are bullish on Glaukos Corporation (GKOS) as it has outperformed the S&P 500 by a wide margin of 25.44% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 15.76%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 16.38% in the last 1 week, and is up 22.9% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 18.52% and the 50-Day Moving Average is 15.75%.The 200 Day SMA reached 56.35% Glaukos Corporation is up 29.16% in the last 3-month period. Year-to-Date the stock performance stands at 51.07%.


Glaukos Corporation (GKOS) : 4 investment research analysts covering Glaukos Corporation (GKOS) have an average price target of $41 for the near short term. The highest target price given by the Brokerage Firm to the stock is $42 and the lowest target is $40 for the short term. Analysts expect the variance to be within $0.82 of the average price.

For the current week, the company shares have a recommendation consensus of Buy. Glaukos Corporation (NYSE:GKOS): stock was range-bound between the intraday low of $36.2601 and the intraday high of $37.53 after having opened at $37.37 on Fridays session. The stock finally closed in the red at $37.37, a loss of -0.32%. The stock remained in the red for the whole trading day. The total traded volume was 931,555 shares. The stock failed to cross $37.53 in Fridays trading. The stocks closing price on Thursday was $37.3.

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eyes anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies, including three pipeline products, namely, the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.